vs
BXP, Inc.（BXP）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是BXP, Inc.的1.0倍（$878.4M vs $872.1M），BXP, Inc.净利率更高（15.3% vs -9.8%，领先25.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 0.8%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 1.3%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
BXP vs EXAS — 直观对比
营收规模更大
EXAS
是对方的1.0倍
$872.1M
营收增速更快
EXAS
高出22.3%
0.8%
净利率更高
BXP
高出25.0%
-9.8%
两年增速更快
EXAS
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $878.4M |
| 净利润 | $133.0M | $-86.0M |
| 毛利率 | — | 70.1% |
| 营业利润率 | — | -9.4% |
| 净利率 | 15.3% | -9.8% |
| 营收同比 | 0.8% | 23.1% |
| 净利润同比 | 53.0% | 90.1% |
| 每股收益（稀释后） | $1.69 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPEXAS
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $878.4M | ||
| Q3 25 | $871.5M | $850.7M | ||
| Q2 25 | $868.5M | $811.1M | ||
| Q1 25 | $865.2M | $706.8M | ||
| Q4 24 | $858.6M | $713.4M | ||
| Q3 24 | $859.2M | $708.7M | ||
| Q2 24 | $850.5M | $699.3M |
净利润BXPEXAS
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $-86.0M | ||
| Q3 25 | $-121.7M | $-19.6M | ||
| Q2 25 | $89.0M | $-1.2M | ||
| Q1 25 | $61.2M | $-101.2M | ||
| Q4 24 | $-228.9M | $-864.6M | ||
| Q3 24 | $83.6M | $-38.2M | ||
| Q2 24 | $79.6M | $-15.8M |
毛利率BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 70.1% | ||
| Q3 25 | 59.3% | 68.6% | ||
| Q2 25 | 59.2% | 69.3% | ||
| Q1 25 | 59.2% | 70.8% | ||
| Q4 24 | 59.7% | 69.0% | ||
| Q3 24 | 59.5% | 69.4% | ||
| Q2 24 | 59.8% | 69.8% |
营业利润率BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | — | -0.3% | ||
| Q1 25 | — | -13.6% | ||
| Q4 24 | — | -122.8% | ||
| Q3 24 | — | -5.6% | ||
| Q2 24 | — | -3.8% |
净利率BXPEXAS
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | -9.8% | ||
| Q3 25 | -14.0% | -2.3% | ||
| Q2 25 | 10.2% | -0.1% | ||
| Q1 25 | 7.1% | -14.3% | ||
| Q4 24 | -26.7% | -121.2% | ||
| Q3 24 | 9.7% | -5.4% | ||
| Q2 24 | 9.4% | -2.3% |
每股收益（稀释后）BXPEXAS
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $-0.45 | ||
| Q3 25 | $-0.77 | $-0.10 | ||
| Q2 25 | $0.56 | $-0.01 | ||
| Q1 25 | $0.39 | $-0.54 | ||
| Q4 24 | $-1.46 | $-4.69 | ||
| Q3 24 | $0.53 | $-0.21 | ||
| Q2 24 | $0.51 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.7B | $2.4B |
| 总资产 | $25.1B | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BXPEXAS
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $964.7M | ||
| Q3 25 | $861.1M | $1.0B | ||
| Q2 25 | $447.0M | $858.4M | ||
| Q1 25 | $398.1M | $786.2M | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.4B | $1.0B | ||
| Q2 24 | $685.4M | $946.8M |
股东权益BXPEXAS
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $2.4B | ||
| Q3 25 | $5.0B | $2.5B | ||
| Q2 25 | $5.3B | $2.5B | ||
| Q1 25 | $5.3B | $2.4B | ||
| Q4 24 | $5.4B | $2.4B | ||
| Q3 24 | $5.8B | $3.2B | ||
| Q2 24 | $5.8B | $3.2B |
总资产BXPEXAS
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $5.9B | ||
| Q3 25 | $26.0B | $5.9B | ||
| Q2 25 | $25.6B | $5.8B | ||
| Q1 25 | $25.4B | $5.7B | ||
| Q4 24 | $26.1B | $5.9B | ||
| Q3 24 | $26.4B | $6.7B | ||
| Q2 24 | $25.5B | $6.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $151.7M |
| 自由现金流经营现金流 - 资本支出 | — | $120.4M |
| 自由现金流率自由现金流/营收 | — | 13.7% |
| 资本支出强度资本支出/营收 | 1.5% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $151.7M | ||
| Q3 25 | $274.2M | $219.9M | ||
| Q2 25 | $353.1M | $89.0M | ||
| Q1 25 | $210.0M | $30.8M | ||
| Q4 24 | $383.7M | $47.1M | ||
| Q3 24 | $286.1M | $138.7M | ||
| Q2 24 | $367.1M | $107.1M |
自由现金流BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $120.4M | ||
| Q3 25 | $231.6M | $190.0M | ||
| Q2 25 | $281.5M | $46.7M | ||
| Q1 25 | $152.6M | $-365.0K | ||
| Q4 24 | $312.5M | $10.7M | ||
| Q3 24 | $234.5M | $112.6M | ||
| Q2 24 | $332.4M | $71.2M |
自由现金流率BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 13.7% | ||
| Q3 25 | 26.6% | 22.3% | ||
| Q2 25 | 32.4% | 5.8% | ||
| Q1 25 | 17.6% | -0.1% | ||
| Q4 24 | 36.4% | 1.5% | ||
| Q3 24 | 27.3% | 15.9% | ||
| Q2 24 | 39.1% | 10.2% |
资本支出强度BXPEXAS
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 3.6% | ||
| Q3 25 | 4.9% | 3.5% | ||
| Q2 25 | 8.2% | 5.2% | ||
| Q1 25 | 6.6% | 4.4% | ||
| Q4 24 | 8.3% | 5.1% | ||
| Q3 24 | 6.0% | 3.7% | ||
| Q2 24 | 4.1% | 5.1% |
现金转化率BXPEXAS
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.97× | — | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.42× | — | ||
| Q2 24 | 4.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
